Thus, CAR-T-cell therapy in MS is a promising but complex approach that requires optimization of safety (minimizing neurotoxicity and infectious risk), personalization (selecting targets (CD19/BCMA/CD38) on the basis of the patient’s immune profile), and combination with other approaches (with IL-2 to maintain Tregs, with anti-CD20 for synergistic B-cell depletion). Here, TNFRSF17 is linked to myeloid sarcoma.